Table 2 MSI status, mutational status and transcriptional subtype of S:CORT FOCUS study patients, according to immune subgroups (immune cold vs. immune NOS).

From: Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia

Variable

Immune cold

Immune NOS

P value

(n = 58)

(n = 235)

MSI status

–

–

0.5172

Stable

57 (98.28%)

224 (95.32%)

–

High

1 (1.72%)

11 (4.68%)

–

APC

–

–

0.6434

Wild type

12 (20.69%)

40 (17.02%)

–

Mutant

46 (79.31%)

195 (82.98%)

–

BRAF

–

–

0.6696

Wild type

49 (84.48%)

206 (87.66%)

–

Mutant

9 (15.52%)

29 (12.34%)

–

KRAS

–

–

0.0013

Wild type

18 (31.03%)

131 (55.74%)

–

Mutant

40 (68.97%)

104 (44.26%)

–

NRAS

–

–

0.3284

Wild type

57 (98.28%)

221 (94.04%)

–

Mutant

1 (1.72%)

14 (5.96%)

–

PIK3CA

–

–

0.1391

Wild type

40 (68.97%)

186 (79.15%)

–

Mutant

18 (31.03%)

49 (20.85%)

–

TP53

–

–

1.0000

Wild type

16 (27.59%)

63 (26.81%)

–

Mutant

42 (72.41%)

172 (73.19%)

–

CRIS classification

–

–

0.0179

CRIS-A

12 (20.69%)

40 (17.02%)

–

CRIS-B

16 (27.59%)

28 (11.91%)

–

CRIS-C

10 (17.24%)

64 (27.23%)

–

CRIS-D

4 (6.9%)

24 (10.21%)

–

CRIS-E

11 (18.97%)

35 (14.89%)

–

Unclassified

5 (8.62%)

44 (18.72%)

–

CMS classification

–

–

0.5616

CMS1

6 (10.34%)

25 (10.64%)

–

CMS2

9 (15.52%)

60 (25.53%)

–

CMS3

7 (12.07%)

21 (8.94%)

–

CMS4

18 (31.03%)

61 (25.96%)

–

Unclassified

18 (31.03%)

68 (28.94%)

–

  1. The data are presented as number of patients (%). Differences compared with the immune subgroups using Pearson’s chi-squared test for categorical variables. Immune cold = patient stratification by collective low-density cell counts for CD3, CD4 and CD8 IHC; immune–not otherwise specified (NOS) = any other combination of CD3, CD4 and CD8 IHC expression.
Back to article page